Zymeworks Inc.: Business Overview, Financials & Competitive Analysis
Zymeworks Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). A clinical-stage biotech with differentiated antibody platforms and Big Pharma partnerships, but requires successful clinical outcomes and funding runway to achieve profitability. While Zymeworks has strong biotech platform capabilities and major pharma partnerships, the company is still clinical-stage with negative EBITDA and burn rate concerns. Recent management restructuring and employee.
What is Zymeworks Inc.'s industry? Zymeworks Inc. (zymeworks.com) operates in Biotechnology / Biopharmaceuticals - Oncology and Immunotherapy. AskCyborg classifies Zymeworks Inc. under Biotechnology / Biopharmaceuticals - Oncology and Immunotherapy in its company registry.
Zymeworks is a clinical-stage biotechnology company that discovers, develops, and commercializes biotherapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Its therapeutic platforms and full...
Cyborg Score thesis
A clinical-stage biotech with differentiated antibody platforms and Big Pharma partnerships, but requires successful clinical...
Read the full analyst-debate transcript →Get the Latest Zymeworks Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeZymeworks Inc. Overview
Pro stress-test →Zymeworks is a clinical-stage biotechnology company that discovers, develops, and commercializes biotherapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Its therapeutic platforms and fully integrated drug development engine provide flexibility to precisely engineer and develop differentiated antibody-based therapeutic candidates.
Strategic Profile
Pro stress-test →The company has strategic partnerships with major pharma including Merck Sharp & Dohme, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, Janssen Biotech, BeiGene, and Exelixis. Lead product zanidatamab is in Phase 1, Phase 2, and Phase 3 clinical trials, with zanidatamab zovodotin in Phase 2 trials for advanced HER2-expressing tumors.
Competitive Landscape
Pro stress-test →Zymeworks competes in the clinical-stage antibody therapeutics space against other developers of bispecific and multifunctional antibody-based drugs. Major competitors include Regeneron, Genmab, Amgen, and other bispecific antibody developers, though Zymeworks differentiates through its proprietary platform technologies.
Industry Context
Zymeworks Inc. operates in Biotechnology / Biopharmaceuticals - Oncology and Immunotherapy.
Key facts
Founded: 2003 · Headquarters: Vancouver, Canada · Employees: 286 · Market cap: $384.52M